SCHEDULE 13G: Adage Capital Management Discloses 5.18% Stake in Karyopharm Therapeutics
Beneficial Ownership Report
Adage Capital Management, L.P., along with its managing members Robert Atchinson and Phillip Gross, has disclosed a beneficial ownership of 5.18% in Karyopharm Therapeutics Inc. as of December 31, 2024.
Summary
- Adage Capital Management, L.P., Robert Atchinson, and Phillip Gross collectively reported beneficial ownership of 6,551,055 shares of Karyopharm Therapeutics Inc. Common Stock.
- This ownership represents 5.18% of the company's outstanding Common Stock.
- The reported shares include 231,213 shares of Common Stock issuable upon the exercise of warrants.
- The percentage of class is calculated based on 126,190,744 shares of Common Stock outstanding as of December 4, 2024, as reported in the company's Definitive Proxy Statement on Schedule 14A.
- The securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing the control of the issuer.
Sentiment
Score: 5
Explanation: The document is a factual disclosure of beneficial ownership and does not contain subjective language or performance metrics that would indicate a strong positive or negative sentiment. The disclosure of a significant institutional stake is generally viewed neutrally to slightly positively.
Positives
- The disclosure of a significant stake by an institutional investor like Adage Capital Management may signal confidence in Karyopharm Therapeutics Inc.'s long-term prospects.
Negatives
- NA
Risks
- NA
Future Outlook
NA
Industry Context
This filing indicates a notable institutional investment in the biotechnology or pharmaceutical sector, specifically in Karyopharm Therapeutics Inc., by a prominent investment management firm. Such disclosures are common and reflect ongoing portfolio adjustments by large investors.
Stakeholder Impact
- Shareholders: The disclosure of a significant stake by a reputable investment firm may be viewed positively, potentially increasing investor confidence and attracting further institutional interest.
Key Dates
| Date | Description |
|---|---|
| 2024-12-04 | Date as of which 126,190,744 shares of Common Stock were reported outstanding in the company's Definitive Proxy Statement on Schedule 14A. |
| 2024-12-31 | Date of event which requires the filing of this statement, reflecting the beneficial ownership position. |
| 2025-02-12 | Date the Schedule 13G statement was signed and filed. |
Keywords
Karyopharm Therapeutics, Adage Capital Management, Beneficial Ownership, Schedule 13G, Common Stock, Institutional Investor, SEC Filing, Investment Management
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.